Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal Squamous Cell Carcinoma
NCT02281955Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Aug 2014
- Primary completion
- Nov 2019
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Cisplatin micelle injection (HA132) in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Progression Free Survival at 2 years. Started Aug 2014; status: completed.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT02281955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02281955.